Anbio Biotechnology Class A Ordinary Shares Asset Resilience Ratio
Anbio Biotechnology Class A Ordinary Shares asset resilience ratio. Anbio Biotechnology Class A Ordinary Shares (NNNN) has an Asset Resilience Ratio of 13.67% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Anbio Biotechnology Class A Ordinary Sha (NNNN) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Anbio Biotechnology Class A Ordinary Shares (2021–2025)
Asset resilience ratio of Anbio Biotechnology Class A Ordinary Shares from 2021 to 2025. This chart shows how Anbio Biotechnology Class A Ordinary Shares's Asset Resilience Ratio has changed over time. Read NNNN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Anbio Biotechnology Class A Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Anbio Biotechnology Class A Ordinary Sha total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $4.13 Million | 13.67% |
| Total Liquid Assets | $4.13 Million | 13.67% |
Asset Resilience Insights
- Moderate Liquidity: Anbio Biotechnology Class A Ordinary Shares has 13.67% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Anbio Biotechnology Class A Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Anbio Biotechnology Class A Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Caina Technology Co. Ltd.
SHE:301122 |
Medical Instruments & Supplies | 19.55% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
Ocumetics Technology Corp
V:OTC |
Medical Instruments & Supplies | 0.00% |
|
Osteopore Ltd
AU:OSX |
Medical Instruments & Supplies | 22.60% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
Anbio Biotechnology Class A Ordinary Shares Asset Resilience Ratio by Year (2021–2025)
Anbio Biotechnology Class A Ordinary Shares asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Anbio Biotechnology Class A Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.67% | $4.13 Million | $30.24 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $18.92 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $15.81 Million | -- |
| 2022-12-31 | 11.22% | $1.57 Million | $13.96 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $4.92 Million | -- |
About Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/… Read more